CD274 and neoplasm: Among the 18 patients included in Cohort 1, where patients received a 12-week treatment with tremelimumab and durvalumab followed by surgery, a pCR rate of 60% and a major-complete pathological response of 80% were observed, with PD-L1 CPS showing no association with outcomes and tumour mutation burden (TMB) demonstrating a non-significant trend of correlation with pCR [34].